Biomarker Predicts Advanced Neoplasia Risk In Patients With Ulcerative Colitis, Study Suggests

MedPage Today (1/31, Minerd) reported “testing for somatic genomic copy number alterations (CNAs) in” patients with ulcerative colitis and “low-grade dysplasia was able to predict risk of advanced neoplasia more accurately than other currently used pathological features, according to a retrospective case-control study.” Researchers found that “among 122 patients followed for approximately 5 years, those who progressed to advanced neoplasia had a significantly higher burden of CNAs in low-grade dysplasia samples compared with non-progressors.” In an “analysis, the burden of CNAs was a ‘very significant’ predictor of advanced neoplasia risk.” The findings were published in Gut.